Latest Insider Transactions at Crispr Therapeutics Ag (CRSP)
This section provides a real-time view of insider transactions for Crispr Therapeutics Ag (CRSP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CRISPR Therapeutics AG to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CRISPR Therapeutics AG's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 17
2019
|
Samarth Kulkarni Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-10.76%
|
$920,000
$46.0 P/Share
|
|
Jun 17
2019
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+9.72%
|
$20,000
$1.81 P/Share
|
|
Jun 10
2019
|
Rodger Novak President |
SELL
Open market or private sale
|
Direct |
50,000
-5.27%
|
$2,250,000
$45.0 P/Share
|
|
Jun 01
2019
|
Samarth Kulkarni Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
741
-0.44%
|
$25,935
$35.57 P/Share
|
|
Apr 29
2019
|
Samarth Kulkarni Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-10.72%
|
$840,000
$42.03 P/Share
|
|
Apr 29
2019
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+9.68%
|
$20,000
$1.81 P/Share
|
|
Mar 05
2019
|
Tony W Ho Executive VP, Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+23.33%
|
$400,000
$40.87 P/Share
|
|
Mar 04
2019
|
Rodger Novak President |
SELL
Open market or private sale
|
Direct |
76,527
-2.52%
|
$3,137,607
$41.19 P/Share
|
|
Mar 01
2019
|
Samarth Kulkarni Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
748
-0.45%
|
$29,172
$39.97 P/Share
|
|
Mar 01
2019
|
Rodger Novak President |
SELL
Open market or private sale
|
Direct |
8,693
-0.84%
|
$347,720
$40.01 P/Share
|
|
Feb 25
2019
|
Rodger Novak President |
SELL
Open market or private sale
|
Direct |
14,780
-1.41%
|
$591,200
$40.0 P/Share
|
|
Jan 09
2019
|
Rodger Novak President |
SELL
Open market or private sale
|
Direct |
82,690
-7.31%
|
$2,894,150
$35.01 P/Share
|
|
Jan 08
2019
|
Rodger Novak President |
SELL
Open market or private sale
|
Direct |
17,310
-1.51%
|
$605,850
$35.09 P/Share
|
|
Jan 02
2019
|
Lawrence Otto Klein CBO & COO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
$580,000
$29.87 P/Share
|
|
Dec 27
2018
|
Vertex Pharmaceuticals (Europe) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
27,461
+0.51%
|
$659,064
$24.95 P/Share
|
|
Dec 26
2018
|
Vertex Pharmaceuticals (Europe) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
12,737
+0.24%
|
$305,688
$24.89 P/Share
|
|
Dec 24
2018
|
Vertex Pharmaceuticals (Europe) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
68,000
+0.42%
|
$1,564,000
$23.69 P/Share
|
|
Dec 21
2018
|
Vertex Pharmaceuticals (Europe) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
22,742
+0.43%
|
$500,324
$22.58 P/Share
|
|
Dec 18
2018
|
Kurt Von Emster Director |
SELL
Open market or private sale
|
Indirect |
69,925
-5.67%
|
$2,027,825
$29.7 P/Share
|
|
Dec 17
2018
|
Kurt Von Emster Director |
SELL
Open market or private sale
|
Indirect |
3,009
-0.24%
|
$99,297
$33.17 P/Share
|
|
Dec 07
2018
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,500
+11.39%
|
$21,500
$1.81 P/Share
|
|
Dec 01
2018
|
Samarth Kulkarni Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
741
-0.51%
|
$28,158
$38.33 P/Share
|
|
Nov 21
2018
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
80,000
-1.88%
|
$1,520,000
$19.25 P/Share
|
|
Sep 01
2018
|
Samarth Kulkarni Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
741
-0.5%
|
$41,496
$56.67 P/Share
|
|
Aug 02
2018
|
Tony W Ho Executive VP, Head of R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
14,631
-39.02%
|
$702,288
$48.43 P/Share
|
|
Aug 01
2018
|
Tony W Ho Executive VP, Head of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+50.0%
|
-
|
|
Jul 05
2018
|
Pablo J Cagnoni Director |
SELL
Open market or private sale
|
Direct |
1,684
-100.0%
|
$104,408
$62.0 P/Share
|
|
Jul 05
2018
|
Pablo J Cagnoni Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,684
+50.0%
|
$8,420
$5.59 P/Share
|
|
Jul 03
2018
|
Pablo J Cagnoni Director |
SELL
Open market or private sale
|
Direct |
5,816
-100.0%
|
$360,592
$62.0 P/Share
|
|
Jul 03
2018
|
Pablo J Cagnoni Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,816
+50.0%
|
$29,080
$5.59 P/Share
|
|
Jun 05
2018
|
Kurt Von Emster Director |
SELL
Open market or private sale
|
Indirect |
920
-4.78%
|
$11,040
$12.51 P/Share
|
|
Jun 05
2018
|
Kurt Von Emster Director |
SELL
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
2,000
-9.42%
|
$10,000
$5.75 P/Share
|
|
Jun 04
2018
|
Samarth Kulkarni Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
741
-0.5%
|
$49,647
$67.13 P/Share
|
|
Jun 01
2018
|
Samarth Kulkarni Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,000
-4.68%
|
$1,020,000
$68.78 P/Share
|
|
Jun 01
2018
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+8.4%
|
$15,000
$1.81 P/Share
|
|
May 17
2018
|
Rodger Novak President |
SELL
Open market or private sale
|
Direct |
75,000
-6.13%
|
$4,500,000
$60.0 P/Share
|
|
May 17
2018
|
Rodger Novak President |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+3.02%
|
$525,000
$7.91 P/Share
|
|
May 15
2018
|
Thomas Woiwode Director |
SELL
Open market or private sale
|
Indirect |
44,000
-3.22%
|
$2,552,000
$58.35 P/Share
|
|
May 15
2018
|
Bradley J Ph D Bolzon Director |
SELL
Open market or private sale
|
Indirect |
44,000
-3.22%
|
$2,552,000
$58.35 P/Share
|
|
May 14
2018
|
Ali Behbahani |
BUY
Other acquisition or disposition
|
Direct |
199
+50.0%
|
-
|
|
May 14
2018
|
Kurt Von Emster Director |
SELL
Open market or private sale
|
Indirect |
400,000
-4.52%
|
$21,600,000
$54.43 P/Share
|
|
May 11
2018
|
Kurt Von Emster Director |
SELL
Open market or private sale
|
Indirect |
250,000
-4.58%
|
$13,000,000
$52.52 P/Share
|
|
May 08
2018
|
Bradley J Ph D Bolzon Director |
SELL
Open market or private sale
|
Direct |
9,241
-11.06%
|
$462,050
$50.77 P/Share
|
|
May 08
2018
|
Thomas Woiwode Director |
SELL
Open market or private sale
|
Direct |
1,653
-22.7%
|
$84,303
$51.45 P/Share
|
|
May 07
2018
|
Bradley J Ph D Bolzon Director |
SELL
Open market or private sale
|
Indirect |
119,709
-4.08%
|
$5,985,450
$50.79 P/Share
|
|
May 07
2018
|
Thomas Woiwode Director |
SELL
Open market or private sale
|
Indirect |
119,709
-4.08%
|
$5,985,450
$50.79 P/Share
|
|
Apr 30
2018
|
Bradley J Ph D Bolzon Director |
SELL
Open market or private sale
|
Indirect |
30,566
-2.03%
|
$1,528,300
$50.28 P/Share
|
|
Apr 30
2018
|
Thomas Woiwode Director |
SELL
Open market or private sale
|
Indirect |
30,566
-2.03%
|
$1,528,300
$50.28 P/Share
|
|
Apr 27
2018
|
Thomas Woiwode Director |
SELL
Open market or private sale
|
Indirect |
11,648
-0.77%
|
$582,400
$50.04 P/Share
|
|
Apr 27
2018
|
Bradley J Ph D Bolzon Director |
SELL
Open market or private sale
|
Indirect |
11,648
-0.77%
|
$582,400
$50.04 P/Share
|